MARKET

GMAB

GMAB

Genmab
NASDAQ
25.82
-0.21
-0.81%
Pre Market: 26.12 +0.3 +1.16% 04:25 03/30 EDT
OPEN
26.16
PREV CLOSE
26.03
HIGH
26.47
LOW
25.78
VOLUME
2.72K
TURNOVER
0
52 WEEK HIGH
35.43
52 WEEK LOW
17.24
MARKET CAP
16.59B
P/E (TTM)
16.81
1D
5D
1M
3M
1Y
5Y
1D
Wix downgraded, TripAdvisor upgraded: Wall Street’s top analyst calls
TipRanks · 2d ago
This Honeywell Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Benzinga · 2d ago
Genmab Price Target Announced at $32.00/Share by Wolfe Research
Dow Jones · 2d ago
Genmab Initiated at Outperform by Wolfe Research
Dow Jones · 2d ago
Wolfe Research Initiates Coverage On Genmab with Outperform Rating, Announces Price Target of $32
Benzinga · 2d ago
UBS Remains a Buy on Genmab A/S (0MGB)
TipRanks · 2d ago
Genmab initiated with an Outperform at Wolfe Research
TipRanks · 3d ago
Genmab held its annual general meeting; agenda item 2 drew 97.26% support
Reuters · 3d ago
More
About GMAB
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.

Webull offers Genmab A/S stock information, including NASDAQ: GMAB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GMAB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GMAB stock methods without spending real money on the virtual paper trading platform.